Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd, will merge with its U.S.-based sister company, Asubio Pharmaceuticals, Inc. As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.

Asubio Pharmaceuticals’ parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research.

Asubio Pharmaceuticals, Inc.’s ongoing clinical trial in patients with acute spinal cord injury, ASBI 603ASCENT Study (SUN13837) has completed enrollment. An analysis and dissemination of the data will be managed by Daiichi Sankyo.

“In line with the Daiichi Sankyo five-year business plan to optimize our business of delivering innovative treatments to patients, consolidating the current Asubio U.S. projects under the company’s overall R&D organization helps us streamline our operations,” said Glenn Gormley, MD, PhD, senior executive officer and global head of R&D, Daiichi Sankyo Company, Ltd., and executive chairman and president, Daiichi Sankyo, Inc.